SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix's upcoming earnings are sparking active debate, especially after the stock traded down in the after-hours session. While revenue was in line with estimates, EPS missed, and some community members are attributing the dip to a tax dispute in Brazil and broader concerns about content. A potential stock split and the impact of increased competition and advertising revenue are also key talking points.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to a proposed private offering of convertible senior notes, leading to community discussion about dilution and its impact on long-term holders; some view this as a strategic move to secure funding before positive catalysts, while others express concern about the company's financial management and potential for further offerings; the community is also debating the recent analyst downgrade and its effect on the stock's trajectory.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to its acquisition of Railbird, a prediction market platform, sparking discussions about the company's expansion into new markets beyond sports betting. While some express excitement about this growth and potential, others are skeptical, citing concerns about profitability and regulatory challenges, with community members closely watching how this move impacts the stock's value.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

ISRG is trending due to strong earnings and raised guidance, sparking debate about its valuation and future growth potential. While some community members celebrate the positive report and anticipate further gains, others express concerns about margin pressures and potential saturation in the US market. Bullish sentiment highlights the company's leadership in robotic surgery and potential for international expansion.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending due to an earnings report that beat expectations but was followed by a weaker-than-expected forecast, sparking concerns about cautious commentary and potential impacts from trade tensions. The community is actively discussing whether the stock is overvalued and anticipating a significant price movement, with some expecting a bounce while others foresee further declines. Some traders believe analysts are paid to pump before ER as a tactic for unloading stock.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amidst speculation of a potential acquisition, with Paramount Skydance reportedly interested in making a bid, although the deal's likelihood is debated. Community chatter revolves around potential offer prices and whether WBD will accept, with some anticipating a bidding war involving other major players like Netflix or Comcast. The stock's movement reflects investor uncertainty surrounding these ongoing acquisition rumors and what price a deal could actually happen at.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending due to a massive surge following news of a $200M financing deal aimed at advancing its schizophrenia treatment. Community chatter revolves around the potential for significant gains, while some traders caution about a possible pump and dump, leading to high volatility. The funding is viewed as a strong indicator of confidence in the drug's approval, sparking debates about its long-term potential versus short-term trading opportunities.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

TERN is trending as investors analyze recent analyst ratings, upcoming catalysts related to their CML and obesity programs, and a strong cash position lasting into 2028. Unusual options activity and insider buying have also caught the attention of traders, though some express concern over lack of recent news and data. Community members are actively discussing potential buyout scenarios and comparing TERN's prospects to others in the GLP-1 space.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as the stock experiences a significant pullback, prompting community discussion about potential bottom levels and future catalysts. Despite the recent downturn, some investors express confidence in the company's long-term prospects, citing a major deal with Microsoft and overall growth in the AI sector. Community members are actively debating whether to buy the dip or wait for further price declines.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs experienced a volatile trading period, initially surging on rare earth mining prospects and fixed-price automotive contracts. However, the stock quickly reversed course following an analyst downgrade and skepticism regarding the viability of the rare earth initiative. Community discussions center on potential acquisitions, the impact of analyst ratings, and overall market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders PR...

Viking Therapeutics jumped to the top of Stocktwits’ trending tickers after a burst of weekend retail chatter tied to deal speculation, rotation flows out of Eli Lilly, and near-term trial milestones.&nbsp;The stock traded nearly 4% higher in overnight trade on Sunday, while retail sentiment was ‘bullish’ amid ‘normal’ message volume.Users pointed to profit-taking in large caps and rotation into Viking, floated the idea of a potential approach from Lilly, and argued that shares are being re-rated since Metsera’s buyout&nbsp;by Pfizer created a perceived price floor for peers.Several&nbsp;watchers on Stocktwits highlighted the company’s next catalyst path. Interest centered on the planned subcutaneous-to-oral maintenance study, which CEO Brian Lian said on a Bernstein call is slated to begin “late this quarter or early next quarter.”&nbsp;Some saw intrigue in the design and flagged a possible “sell-the-news” setup, while others anticipated updates on spend and Phase 3 enrollment on the upcoming earnings call and kept partnership or buyout scenarios “in play.”<stembedurl>https://stocktwits.com/saifnila2/message/631119435</stembedurl><stembedurl>https://stocktwits.com/saifnila2/message/631074611</stembedurl>Last month,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/viking-therapeutics-stock-boost-pfizer-metsera-deal-btig-retail-slams-rivals-inferior-pipelines/chDhieAR3P5">BTIG suggested that Viking is benefiting from Pfizer’s agreement</a> to acquire Metsera, which expands Big Pharma's appetite for cardiometabolic assets. The research firm reiterated its ‘Buy’ rating with a $125 target, citing sharpened strategic optionality following recent M&amp;A, while Roche’s takeover of 89bio reinforced expectations for continued deal activity across the obesity and NASH pipelines.Retail voices remained split on strategy. Some argued Viking should not “go it alone,” given its lean headcount and would be better served by a larger commercial partner. Others framed the setup more broadly, citing pipeline breadth, potential rate-cut tailwinds, patent positioning, and a “David vs Goliath” narrative that could keep both institutions and retail engaged.<stembedurl>https://stocktwits.com/Reaperofmars1/message/631069156</stembedurl><stembedurl>https://stocktwits.com/LastResort/message/631074413</stembedurl>Investors also revisited&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/viking-short-interest-hits-5-year-high-after-weight-loss-drug-stumble/chss46sRdKN">the August data on oral VK2735</a>, noting a double-digit mean weight loss at 13 weeks, with tolerability viewed as manageable,&nbsp;although not as pristine as in the early studies.&nbsp;Several analysts, including B. Riley, Leerink, Jefferies, Stifel, and JPMorgan, called the selloff that followed overdone, emphasizing dose flexibility, maintenance positioning, and the potential to modulate gastrointestinal events through slower titration.<a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 26% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts 

Shares rose nearly 4% overnight as investors tied Viking’s upcoming trial and its positioning to renewed obesity-drug deal momentum after Pfizer’s Metsera buyout.

Equity

Can PFE Successfully Return to the Obesity Space With Metsera Buyout?

Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.

Company News for Sep 23, 2025

Companies In The News Are: ORCL, TAP, AAPL, MTSR, PFE.

Shares of Viking Therapeutics rose 3.4% to $26.25 on Monday and extended gains after hours,&nbsp;with a Wall Street research firm suggesting the biopharma is benefiting from Pfizer’s buyout offer for Metsera as it looks to bolster its obesity drug pipeline.BTIG reiterated a ‘Buy’ rating and $125 price target on&nbsp;Viking’s stock, saying the transaction sharpens&nbsp;the company’s&nbsp;clinical updates and strategic optionality while bolstering sentiment ahead of key readouts. The commentary followed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/89bio-stock-surges-roche-3-5b-buyout-wall-street-analyst-cautious/chDdNVaR3br">Roche’s acquisition of 89bio</a>, signaling increased deal activity in the biotech space.Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> surged to an all-time high Monday, marking their biggest one-day gain ever.&nbsp;As part of the deal, Pfizer will pay Metsera $47.50 in cash per share, giving the company an enterprise value of $4.9 billion. If three clinical milestones are achieved, additional payments of $22.50 per Metsera share will be made, bringing the total value of the deal to as much as $7.3 billion. The deal is expected to close in the fourth quarter of 2025, pending approvals.Metsera, a clinical-stage biotech developing therapies for obesity and cardiometabolic diseases, will add four differentiated programs to Pfizer's pipeline. The assets include weekly and monthly injectable GLP-1 receptor agonists, two orally delivered GLP-1 candidates, and MET-233i, a monthly injectable amylin analog. The company previously discontinued its own obesity candidate Danuglipron.Viking was also in the spotlight, with Daniel Newman, CEO of Futurum Equities,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/danielnewmanUV/status/1970178447411683535">posting on X</a> that Viking’s valuation “just got a massive shot in the arm with the Pfizer deal to buy Metsera,” describing Metsera’s GLP-1 program as “a far less exciting GLP” and arguing that Viking is “worth far more than $7.2 billion.”On Stocktwits, retail sentiment was ‘extremely bullish’ for both Pfizer and Metsera amid ‘extremely high’ message volume, while Viking drew ‘bullish’ sentiment alongside ‘high’ activity.One bullish user said Viking management had likely rejected lowball offers from large pharma, leaving rivals to acquire ‘inferior pipelines.<stembedurl>https://stocktwits.com/deerhtide/message/629602680</stembedurl>Another pointed to debate over whether Viking should pursue a buyout or go-it-alone strategy, adding that CEO Brian Lian’s stake of more than two million shares aligns him with investors. The user disclosed holding 83,000 shares, calling the position conviction-driven.<stembedurl>https://stocktwits.com/SauceMan912/message/629604221</stembedurl>So far this year,&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> is down 4.5%, Metsera’s shares have more than doubled, and&nbsp;<a href="https://stocktwits.com/symbol/VKTX">Viking Therapeutics’ stock</a> has fallen 34.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

U.S. equities gained in Monday’s afternoon trade amid a surge in big tech stocks like Nvidia Corp. (NVDA), Apple Inc. (AAPL), and Oracle Corp. (ORCL), erasing the weakness observed during the morning session.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was up 0.41% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, rose 0.54%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, gained 0.13%.Here are the top stocks making the biggest moves in Monday’s afternoon trade:<a href="https://stocktwits.com/symbol/NVDA">Nvidia Corp. (NVDA)</a>Nvidia’s shares were up nearly 4% in Monday’s afternoon session, hitting an all-time high, after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-plans-100-billion-investment-to-build-10-gw-network-with-openai/chDQM6aR32p">announced</a> that it will invest up to $100 billion in OpenAI as part of a new partnership with the AI startup. Nvidia will supply and finance at least 10 gigawatts of advanced computing systems for the development of OpenAI’s next-generation AI models.<a href="https://stocktwits.com/symbol/NVDA">NVDA stock</a> is up 36% year-to-date.<a href="https://stocktwits.com/symbol/MTSR">Metsera Inc. (MTSR)</a>Metsera shares were up by over 62% in Monday’s afternoon trade after Pfizer Inc. (PFE)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/metsera-stock-surges-pre-market-after-pfizer-confirms-acquisition/chDQNVhR3cy">announced</a> that it will acquire the former for an upfront payment of $4.9 billion. Pfizer will pay $47.50 per share for Metsera, and it has also promised a bonus payment of $22.50 per share if Metsera’s drugs hit certain milestones.<a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> is up 112% year-to-date.<a href="https://stocktwits.com/symbol/ORCL">Oracle Corp. (ORCL)</a>Oracle shares were up nearly 5% in Monday’s afternoon trade after a White House official&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-government-wont-have-any-take-equity-stake-in-tiktok-new-entity/chDQsItR32F">confirmed</a> that the company would provide security and help oversee the recreation of a U.S. version of TikTok. Oracle also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-clay-magouyrk-mike-sicilia-co-ceo-safra-catz/chDQFqRR329">appointed</a> Clay Magouyrk and Mike Sicilia as co-CEOs, replacing Safra Catz.<a href="https://stocktwits.com/symbol/ORCL">ORCL stock</a> is up 94% year-to-date.<a href="https://stocktwits.com/symbol/AAPL">Apple Inc. (AAPL)</a>Apple shares were up nearly 4% in Monday’s afternoon session after analysts at Bank of America&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-stock-price-target-hike-dan-ives-strong-iphone-17-demand/chDQFLSR323">observed</a> that the iPhone 17’s ship times are significantly higher than those of the iPhone 16.<a href="https://stocktwits.com/symbol/AAPL">AAPL stock</a> is up 2% year-to-date.<a href="https://stocktwits.com/symbol/COMP">Compass Inc. (COMP)</a>Compass shares were down by nearly 17% in Monday’s afternoon trade after the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anywhere-real-estate-stock-rocketed-51-pre-market-today/chDQFdrR325">announcement</a> of a merger with Anywhere Real Estate Inc. (HOUS) in an all-stock transaction.<a href="https://stocktwits.com/symbol/COMP">COMP stock</a> is up 34% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/richtech-robotics-stock-price-target-hike-retail-chatter/chDQvd2R32M">Richtech Robotics Stock Sees Retail Chatter Double In A Day: Analyst Says Company's Longer-Term Visibility Is Improving</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Nvidia, Metsera, Oracle, Apple, Compass: Stocks Making The Biggest Moves Today

Nvidia’s shares were up nearly 4% in Monday’s afternoon session, hitting an all-time high, after the company announced that it will invest up to $100 billion in OpenAI as part of a new partnership with the AI startup.

Pfizer Inc. (PFE) on Monday said that it will acquire biopharmaceutical company Metsera (MTSR) for $47.50 per share in cash at closing.The upfront purchase price of $47.50 per share represents a premium of 43% from Metsera’s closing share price on Friday. The deal represents a total enterprise value of approximately $4.9 billion for Metsera.Metsera shareholders will also receive a non-transferable contingent value right (CVR) entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. The transaction is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250922965053/en/Pfizer-to-Acquire-Metsera-and-its-Next-Generation-Obesity-Portfolio">expected</a> to close in the fourth quarter of 2025, subject to the satisfaction of customary closing conditions.Shares of Metsera soared 59% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MTSR">MTSR</a> jumped from ‘bullish’ to ‘extremely bullish' territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.New York City-based Metsera is a clinical-stage biopharmaceutical company developing medicines for obesity and cardiometabolic diseases.<a href="https://stocktwits.com/symbol/PFE">Pfizer</a> said on Monday that the proposed acquisition will add four highly differentiated clinical-stage programs to Pfizer’s pipeline, including MET-097i, a weekly and monthly injectable GLP-1 receptor agonist, and MET-233i, a monthly amylin analog candidate, in addition to two other oral GLP-1 receptor agonists expected to begin clinical trials soon. GLP-1 receptor agonists are a class of medications that mimic the effects of the body's natural hormone glucagon-like peptide-1 (GLP-1) to treat type 2 diabetes and obesity. Amylin analogs, likewise, can lead to weight loss.“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area,” said Pfizer CEO Albert Bourla. Pfizer scrapped its own obesity drug candidate, Danuglipron, earlier this year.The Financial Times had on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-metsera-7b-buyout-obesity-drug-race-lilly-novo/chDQXfYR3c9">reported</a> that the two companies could announce a deal as early as Monday.While Pfizer’s stock has declined 9% so far in 2025, Metsera’s stock has risen 25.7% over the same period.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/micron-stock-gets-a-price-target-hike-from-stifel/chDQNFpR3cz">Micron Stock Gets A Price Target Hike From Stifel Ahead Of Q4 Earnings – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Metsera Stock Surges 59% Pre-Market After Pfizer Confirms Acquisition – Here Are The Details

The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday.

Pfizer is reportedly preparing to buy weight-loss biotech Metsera in a deal that could be worth as much as $7.3 billion.The New York-based drugmaker would apparently pay $47.50 a share upfront and another $22.50 tied to milestones, a sharp premium to Metsera’s recent price of $33.32. An announcement could come as early as Monday, barring last-minute delays, according to a Financial Times&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/aee4a71c-7ad6-4cde-852f-720a97542fac">report</a>,&nbsp;which cited two people familiar with the matter.The move comes after Pfizer scrapped its own obesity drug candidate, danuglipron, earlier this year. Metsera, which is listed in one of 2025’s biggest biotech IPOs, has drawn interest across the sector with MET-097i, a GLP-1 therapy that produced 11.3% weight loss over 12 weeks in a mid-stage trial.&nbsp;The company is also developing a monthly version of the shot, an amylin-based treatment aimed at avoiding muscle loss, and an oral pill. Pfizer shares, now worth about half their 2021 pandemic peak, closed Friday at $24, valuing the company at $136 billion.&nbsp;CEO Albert Bourla has been under pressure to reignite growth, with Pfizer’s last major deal being the $43 billion purchase of cancer drugmaker Seagen in 2023. A Metsera acquisition would put it in direct competition with Eli Lilly and Novo Nordisk, whose blockbuster GLP-1 drugs Zepbound and Wegovy are expanding into pill form.On Stocktwits, retail sentiment for both Pfizer and Metsera was ‘bullish’, with message volume ‘normal’ for Pfizer and ‘high’ for Metsera.One user&nbsp;labeled the reported deal value&nbsp;a “lousy premium” to Metsera’s recent trading levels and argued the company’s management may be selling too cheaply. The user added that Pfizer may have avoided a bigger gamble on Viking Therapeutics ahead of late-stage trials.<stembedurl>https://stocktwits.com/biolover/message/629465706</stembedurl>Another bullish user said that the acquisition could ultimately be seen as an $80-per-share buyout opportunity.<stembedurl>https://stocktwits.com/vu_jade/message/629466433</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> has declined 4.6% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> has risen 25.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up

Pfizer is pushing into the booming weight-loss market after its own drug setback, as rivals Eli Lilly and Novo Nordisk lead the field.

Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Metsera Inc. (MTSR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

The mean of analysts' price targets for Metsera Inc. (MTSR) points to a 55.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MTSR News

MTSRMetsera Inc